Immuno-oncology beyond checkpoint inhibitors
If any company is interested in sponsoring, please contact email@example.com.
Please register online. Online registration is free for CABS members and $10 for non-members. You can become a CABS member and register online free. Onsite registration is $10.
When register, please enter your affiliation and name on your photo ID which is required at onsite check-in.
1:00-1:30PM check-in, onsite registration and networking
1. After CD19: CAR-T for solid tumor
Cheng Liu, Founder and CEO, Eureka Therapeutics
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.
2. Targeting patient-specific neoantigens using a personalized, Live-Attenuated Double Deleted Listeria monocytogenes (pLADD) Immunotherapy
Chan C. Whiting, Director of Immune Monitoring and Biomarker Development, Aduro Biotech
Dr. Chan Whiting is currently the Director of Immune Monitoring and Biomarker Development at Aduro Biotech. She received her Ph.D. at UCLA in the Department of Microbiology and Immunology where her thesis focused on identifying and characterizing novel signal transducers involved in cytokine and T cell receptor (TCR) signaling pathways. She did post-doctoral training in chemokine biology at Amgen followed by research into E3 ligases in the development of autoimmune diseases at Stanford University. Prior to joining Aduro Biotech, Dr. Whiting has worked for systems biology companies including Entelos, Inc. and Ingenuity Systems (currently Qiagen) in developing mathematical mechanistic models and other in silico computational tools for target discovery and validation for autoimmunity, infectious diseases and oncology. She applies systems-based technologies along with traditional immune assays towards biomarker development efforts in immune oncology at Aduro.
3. Oncolytic viral immunotherapy for the treatment of advanced cancers
Caroline J Breitbach, Vice President, Translational Development, Turnstone Biologics
Caroline J Breitbach is Vice President, Translational Development at Turnstone Biologics, focusing on the development of an oncolytic viral immunotherapy for the treatment of patients with advanced cancers. Caroline was previously Vice President, Clinical & Translational Research at SillaJen Biotherapeutics (formerly Jennerex Biotherapeutics), where she oversaw Phase 1 and 2 clinical studies an oncolytic vaccinia virus. Caroline received her undergraduate degree at McGill University in Montreal, Canada. She subsequently joined Dr John Bell’s group at the University of Ottawa in Ottawa, Canada where she evaluated acute effects of oncolytic viruses on the tumor immune microenvironment.
CABS Member Online – $0 (USD)
Non-member Online – $10 (USD)